News Release
More-
July 1, 2025
New Launch of TAVALISSE® for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea -
June 24, 2025
Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers -
May 8, 2025
Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System (ToSTNeT-3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares -
May 7, 2025
The New Five-Years Medium-Term Management Plan "Beyond 80" -
May 7, 2025
Notice Concerning Dividends of Surplus (Increase in Dividend)
Topics
More-
June 27, 2025
Status of Dialogue with Shareholders and Investors (June 27, 2025) -
May 7, 2025
Financial Results (May 7, 2025) -
May 7, 2025
R&D Pipeline as of May 2025 -
February 3, 2025
The Third Quarter of FY2024 (February 3, 2025) -
November 5, 2024
The Second Quarter of FY2024 (November 5, 2024)
